8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 18, 2026·SEC
Protalix BioTherapeutics, Inc.(PLX)Earnings, Financials & Key Ratios
PLX•AMEX
$2.30
Price updated Jun 27, 2026
AboutProtalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.Show more
- Revenue$53M-1.2%
- EBITDA-$4M-177.3%
- Net Income-$7M-325.2%
- EPS (Diluted)-0.08-329.8%
- Gross Margin47.85%-12.1%
- EBITDA Margin-7.65%-178.2%
- Operating Margin-10.43%-242.2%
- Net Margin-12.52%-328.0%
- ROE-14.44%-289.1%
PLX Price & Volume
Protalix BioTherapeutics, Inc. (PLX) stock price & volume — 10-year historical chart
Loading chart...
Volatile Milestone Revenue Masks Structural Profitability Risks
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial Position:Vulnerable
Cash Flow:Mixed
Primary Risk:Liquidity and milestone dependency
"Protalix BioTherapeutics faces a challenging path to sustainable growth, as its reliance on lumpy milestone payments and international shipments creates significant earnings volatility. While the company has successfully reduced its total debt from $27.6M in 2024Q2 to $8.5M in 2026Q1, the persistent $366.7M accumulated deficit continues to weigh heavily on the equity base. Investors should monitor whether the recent 2026Q1 net income of $18.3M represents a durable inflection point or merely a temporary fluctuation in a historically inconsistent commercial model."
Verdict Logic
while the company reached a $41.7M cash position in 2026Q1, the historical pattern of negative operating cash flow and a -27.35 TTM P/E ratio suggest that the current valuation may not yet be supported by sustainable commercial scale.
PLX Growth Metrics
Protalix BioTherapeutics, Inc. (PLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years28.3%
5 Years-3.46%
3 Years3.45%
TTM27.8%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM292.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM334.92%
Return on Capital
10 Years-51.46%
5 Years-39.04%
3 Years10.67%
Last Year-10.62%
PLX Recent Earnings
Protalix BioTherapeutics, Inc. (PLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.22+2300.0%
$0.01
Rev
$34M+193.5%
$12M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.07-800.0%
$0.01
Rev
$9M-50.1%
$18M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.03-50.0%
$0.06
Rev
$18M+25.3%
$14M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.00-93.3%
$0.03
Rev
$16M+16.1%
$13M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.22vs $0.01+2300.0% | $34Mvs $12M+193.5% |
| Q2 2026 | Mar 18, 2026 | $0.07vs $0.01-800.0% | $9Mvs $18M-50.1% |
| Q4 2025 | Nov 13, 2025 | $0.03vs $0.06-50.0% | $18Mvs $14M+25.3% |
| Q3 2025 | Aug 14, 2025 | $0.00vs $0.03-93.3% | $16Mvs $13M+16.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Protalix BioTherapeutics, Inc. (PLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.30 | $185.31M | -27.35 | -1.23% | -12.52% | -14.44% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $16.85 | $1.78B | -2.36 | 15.58% | 2.98% | 4.89% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — |
Compare PLX vs Peers
Protalix BioTherapeutics, Inc. (PLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLX SEC Filings & Documents
Protalix BioTherapeutics, Inc. (PLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PLX Frequently Asked Questions
Protalix BioTherapeutics, Inc. (PLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Protalix BioTherapeutics, Inc.'s revenue?
Protalix BioTherapeutics, Inc. (PLX) reported $76.4M in revenue for fiscal year 2025.
How fast is Protalix BioTherapeutics, Inc. growing?
Protalix BioTherapeutics, Inc. (PLX) saw revenue decline by 1.2% over the past year.
Is PLX profitable?
Yes, Protalix BioTherapeutics, Inc. (PLX) is profitable, generating $15.3M in net income for fiscal year 2025 (-12.5% net margin).
Dividend & Returns
What is PLX's return on equity?
Protalix BioTherapeutics, Inc. (PLX) has a return on equity (ROE) of -14.4%. Negative ROE indicates the company is unprofitable.
What is Protalix BioTherapeutics, Inc.'s free cash flow?
Protalix BioTherapeutics, Inc. (PLX) generated $14.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.